Literature DB >> 16826219

Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms.

John C Reed1.   

Abstract

Cell death is a normal facet of human physiology, ensuring tissue homeostasis by offsetting cell production with cell demise. Neoplasms arise in part because of defects in physiological cell death mechanisms, contributing to pathological cell expansion. Defects in normal cell death pathways also contribute to cancer progression by permitting progressively aberrant cell behaviors, while also desensitizing tumor cells to immune-mediated attack, radiation, and chemotherapy. Through basic research, much has been learned about the molecular mechanisms responsible for cell turnover and how tumors escape cell death. By exploiting this knowledge base, several innovative strategies for eradicating malignancies have materialized that are based on restoration of natural pathways for cell autodestruction. Some of these strategies have advanced into human clinical trials. Several of the current strategies based on targeting core components of the cell death machinery for cancer therapy are reviewed here, and a summary of progress toward clinical applications is provided.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16826219     DOI: 10.1038/ncponc0538

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN: 1743-4254


  59 in total

Review 1.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

2.  Modulation of fungal sensitivity to staurosporine by targeting proteins identified by transcriptional profiling.

Authors:  Andreia S Fernandes; A Pedro Gonçalves; Ana Castro; Telma A Lopes; Rui Gardner; N Louise Glass; Arnaldo Videira
Journal:  Fungal Genet Biol       Date:  2011-10-05       Impact factor: 3.495

3.  Apoptosis and Compensatory Proliferation Signaling Are Coupled by CrkI-Containing Microvesicles.

Authors:  Kajal H Gupta; Josef W Goldufsky; Stephen J Wood; Nicholas J Tardi; Gayathri S Moorthy; Douglas Z Gilbert; Janet P Zayas; Eunsil Hahm; Mehmet M Altintas; Jochen Reiser; Sasha H Shafikhani
Journal:  Dev Cell       Date:  2017-06-19       Impact factor: 12.270

Review 4.  Manipulating the apoptotic pathway: potential therapeutics for cancer patients.

Authors:  Darcy J P Bates; Lionel D Lewis
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 5.  Antigen cross-presentation: extending recent laboratory findings to therapeutic intervention.

Authors:  T W H Flinsenberg; E B Compeer; J J Boelens; M Boes
Journal:  Clin Exp Immunol       Date:  2011-05-11       Impact factor: 4.330

Review 6.  Apoptotic pathways as a therapeutic target for colorectal cancer treatment.

Authors:  Aman M Abraha; Ezra B Ketema
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

7.  Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Jun Tian; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

8.  The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage.

Authors:  Ho-Chou Tu; Decheng Ren; Gary X Wang; David Y Chen; Todd D Westergard; Hyungjin Kim; Satoru Sasagawa; James J-D Hsieh; Emily H-Y Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-14       Impact factor: 11.205

9.  Computational structure-activity relationship analysis of non-peptide inducers of macrophage tumor necrosis factor-alpha production.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Liliya N Kirpotina; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2008-09-05       Impact factor: 3.641

10.  Inhibition of novel protein kinase C-epsilon augments TRAIL-induced cell death in A549 lung cancer cells.

Authors:  Matthias Felber; Jürgen Sonnemann; James F Beck
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.